Optimum platelet inhibition after coronary artery bypass surgery: a prospective, randomised trial comparing platelet aggregation using low- and medium-dose aspirin and clopidogrel

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN55334531

Enrollment

108

Registered

2003-09-12

Start date

2002-08-28

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary artery bypass grafting (CABG) Surgery

Interventions

Patients will be randomised into treatment allocation to receive either 100 mg aspirin, 325 mg aspirin or identically encapsulated 75 mg clopidogrel daily for 5 days.

Eligibility

Inclusion criteria

Inclusion criteria: 72 Patients and 36 controls will be recruited from patients proceeding to coronary artery bypass surgery.

Exclusion criteria

Exclusion criteria: Does not match inclusion criteria

Design outcomes

Primary

Measure	Time frame
Platelet aggregation ratio at 5 days.	—

Secondary

Measure	Time frame
Not provided at time of registration	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026